Lassus H - Search Results

1

Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome.

Huang J, Zhang L, Greshock J, Colligon TA, Wang Y, Ward R, Katsaros D, Lassus H, Butzow R, Godwin AK, Testa JR, Nathanson KL, Gimotty PA, Coukos G, Weber BL, Degenhardt Y. Huang J, et al. Among authors: lassus h. Genes Chromosomes Cancer. 2011 Aug;50(8):606-18. doi: 10.1002/gcc.20883. Epub 2011 May 11. Genes Chromosomes Cancer. 2011. PMID: 21563232 Free PMC article.

2

Comparison of serous and mucinous ovarian carcinomas: distinct pattern of allelic loss at distal 8p and expression of transcription factor GATA-4.

Lassus H, Laitinen MP, Anttonen M, Heikinheimo M, Aaltonen LA, Ritvos O, Butzow R. Lassus H, et al. Lab Invest. 2001 Apr;81(4):517-26. doi: 10.1038/labinvest.3780260. Lab Invest. 2001. PMID: 11304571 Free article.

3

Allelic analysis of serous ovarian carcinoma reveals two putative tumor suppressor loci at 18q22-q23 distal to SMAD4, SMAD2, and DCC.

Lassus H, Salovaara R, Aaltonen LA, Butzow R. Lassus H, et al. Am J Pathol. 2001 Jul;159(1):35-42. doi: 10.1016/S0002-9440(10)61670-7. Am J Pathol. 2001. PMID: 11438451 Free PMC article.

4

Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients.

Moilanen J, Lassus H, Leminen A, Vaheri A, Bützow R, Carpén O. Moilanen J, et al. Among authors: lassus h. Gynecol Oncol. 2003 Aug;90(2):273-81. doi: 10.1016/s0090-8258(03)00262-2. Gynecol Oncol. 2003. PMID: 12893187

5

Glycodelin in ovarian serous carcinoma: association with differentiation and survival.

Mandelin E, Lassus H, Seppälä M, Leminen A, Gustafsson JA, Cheng G, Bützow R, Koistinen R. Mandelin E, et al. Among authors: lassus h. Cancer Res. 2003 Oct 1;63(19):6258-64. Cancer Res. 2003. PMID: 14559812

6

Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma.

Erkinheimo TL, Lassus H, Sivula A, Sengupta S, Furneaux H, Hla T, Haglund C, Butzow R, Ristimäki A. Erkinheimo TL, et al. Among authors: lassus h. Cancer Res. 2003 Nov 15;63(22):7591-4. Cancer Res. 2003. PMID: 14633672

7

Distinct subtypes of serous ovarian carcinoma identified by p53 determination.

Lassus H, Leminen A, Lundin J, Lehtovirta P, Butzow R. Lassus H, et al. Gynecol Oncol. 2003 Dec;91(3):504-12. doi: 10.1016/j.ygyno.2003.08.034. Gynecol Oncol. 2003. PMID: 14675668

8

ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma.

Lassus H, Leminen A, Vayrynen A, Cheng G, Gustafsson JA, Isola J, Butzow R. Lassus H, et al. Gynecol Oncol. 2004 Jan;92(1):31-9. doi: 10.1016/j.ygyno.2003.10.010. Gynecol Oncol. 2004. PMID: 14751135

9

Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma.

Erkinheimo TL, Lassus H, Finne P, van Rees BP, Leminen A, Ylikorkala O, Haglund C, Butzow R, Ristimäki A. Erkinheimo TL, et al. Among authors: lassus h. Clin Cancer Res. 2004 Jan 15;10(2):538-45. doi: 10.1158/1078-0432.ccr-0132-03. Clin Cancer Res. 2004. PMID: 14760075

10

Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma.

Lassus H, Sihto H, Leminen A, Nordling S, Joensuu H, Nupponen NN, Butzow R. Lassus H, et al. Br J Cancer. 2004 Dec 13;91(12):2048-55. doi: 10.1038/sj.bjc.6602252. Br J Cancer. 2004. PMID: 15583695 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45 results

Search Page

Filters